The Function of Transforming Growth Factor 2 in Facilitating Inflammasome Activation to Enhance the Development of Myopia via Complement System
Cells · 2025
DOI: 10.3390/cells14161295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sheng-Chun Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. Hauptthemen laut MEDLINE: Inflammasomes, Myopia, Complement System Proteins, Complement Activation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, China Medical University Hospital, China Medical University.
Abstract (Originalsprache)
Myopia is one of the major public health conditions with significant complications. This study investigates the role of transforming growth factor (TGF)-β2, complement activation, and inflammasome pathways in myopia progression using a Brown Norway rat model. Myopia was induced, and complement regulation was manipulated using gene therapy via adeno-associated virus (AAV) vectors delivering CD55 or CD55 siRNA. Results showed that TGF-β2 exacerbated myopia by upregulating complement components C3 and C5, suppressing CD55, and activating inflammasome pathways through nuclear factor (NF)-κB signaling, leading to axial elongation and increased refractive errors. Overexpression of CD55 via AAV gene therapy effectively counteracted these effects, reducing axial length elongation and inflammation by suppressing inflammasome markers interleukin (IL)-1β and NLR family pyrin domain containing 3 (NLRP3), as confirmed by real-time quantitative PCR and immunofluorescence analyses. Conversely, silencing CD55 intensified TGF-β2-induced effects, further promoting axial elongation and inflammation. These findings highlight the critical role of CD55 in modulating TGF-β2-driven complement and inflammasome activation during myopia progression. The study suggests that gene therapy targeting CD55 could serve as a novel therapeutic strategy to mitigate myopia and related inflammatory processes, offering a promising avenue for managing this significant public health challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.
- School of Chinese Medicine, China Medical University, Taichung 406040, Taiwan.
- Department of Chemistry, National Central University, Taoyuan 320317, Taiwan.
- Ph.D. Program for Health Science and Industry, China Medical University, Taichung 406040, Taiwan.
- Department of Food Nutrition and Health Biotechnology, Asia University, Taichung 413305, Taiwan.
- Division of Chinese Medicine, Asia University Hospital, Taichung 413505, Taiwan.
ORCID-Profile: Chi-Fong Lin, Peng-Tai Tien, Lei Wan
Förderung
- National Science and Technology Council
- China Medical University Hospital
- China Medical University
- Taichung Tzu Chi Hospital
Zitieren
APA
Lin, S. C., Hsu, Y. A., Lin, C. F., Chen, C. S., Tien, P. T., Wang, Y. C., Chang, C. Y., Lin, E. S., Chen, J. J., Wu, M. Y., Lin, H. J., & Wan, L. (2025). The Function of Transforming Growth Factor 2 in Facilitating Inflammasome Activation to Enhance the Development of Myopia via Complement System. Cells. https://doi.org/10.3390/cells14161295
Vancouver
Lin SC, Hsu YA, Lin CF, Chen CS, Tien PT, Wang YC, et al. The Function of Transforming Growth Factor 2 in Facilitating Inflammasome Activation to Enhance the Development of Myopia via Complement System. Cells. 2025. doi:10.3390/cells14161295
BibTeX
@article{Lin2025,
author = {Lin, Sheng-Chun and Hsu, Yu-An and Lin, Chi-Fong and Chen, Chih-Sheng and Tien, Peng-Tai and Wang, Yao-Chien and Chang, Ching-Yao and Lin, En-Shyh and Chen, Jamie Jiin-Yi and Wu, Ming-Yen and Lin, Hui-Ju and Wan, Lei},
title = {The Function of Transforming Growth Factor 2 in Facilitating Inflammasome Activation to Enhance the Development of Myopia via Complement System},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14161295}
}
EUVIMED